{"fetched":"2026-09-09","decisions":[{"body":"G-BA","country":"Germany","drugId":"datopotamab-deruxtecan","product":"Datopotamab deruxtecan","brand":"Datroway","title":"Datopotamab deruxtecan (Neues Anwendungsgebiet: Mammakarzinom, triple-negativ, Erstlinie)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-09-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1396/","note":"Neues Anwendungsgebiet: Mammakarzinom, triple-negativ, Erstlinie"},{"body":"G-BA","country":"Germany","drugId":"pirtobrutinib","product":"Pirtobrutinib","brand":"Jaypirca","title":"Pirtobrutinib (Neues Anwendungsgebiet: Chronische lymphatische Leukämie (CLL), Monotherapie)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-09-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1397/","note":"Neues Anwendungsgebiet: Chronische lymphatische Leukämie (CLL), Monotherapie"},{"body":"G-BA","country":"Germany","drugId":"durvalumab","product":"Durvalumab","brand":"Imfinzi","title":"Durvalumab (Neues Anwendungsgebiet: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, neoadjuvante und adjuvante Kombination mit FLOT-Chemotherapie gefolgt von adjuvanter Monotherapie)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1336/","note":"Neues Anwendungsgebiet: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, neoadjuvante und adjuvante Kombination mit FLOT-Chemotherapie gefolgt von adjuvanter Monotherapie"},{"body":"G-BA","country":"Germany","drugId":"enfortumab-vedotin","product":"Enfortumab vedotin","brand":"Padcev","title":"Enfortumab Vedotin (Neues Anwendungsgebiet: Muskelinvasives Blasenkarzinom, neoadjuvante/adjuvante Therapie nach Zystektomie, in Kombination mit Pembrolizumab)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1384/","note":"Neues Anwendungsgebiet: Muskelinvasives Blasenkarzinom, neoadjuvante/adjuvante Therapie nach Zystektomie, in Kombination mit Pembrolizumab"},{"body":"G-BA","country":"Germany","drugId":"sacituzumab-govitecan","product":"Sacituzumab govitecan","brand":"Trodelvy","title":"Sacituzumab govitecan (Neues Anwendungsgebiet: Mammakarzinom, triple-negativ, Erstlinie)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1386/","note":"Neues Anwendungsgebiet: Mammakarzinom, triple-negativ, Erstlinie"},{"body":"G-BA","country":"Germany","drugId":"serplulimab","product":"Serplulimab","brand":"Hetronifly","title":"Serplulimab (Aufhebung des regulatorischen Orphanstatus: Kleinzelliges Lungenkarzinom, in Kombination mit Carboplatin und Etoposid, Erstlinie)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1390/","note":"Aufhebung des regulatorischen Orphanstatus: Kleinzelliges Lungenkarzinom, in Kombination mit Carboplatin und Etoposid, Erstlinie"},{"body":"G-BA","country":"Germany","drugId":"serplulimab","product":"Serplulimab","brand":"Hetronifly","title":"Serplulimab (Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, nicht-plattenepithelial, EGFR-, ALK- und ROS-negativ, Erstlinie, Kombination mit Carboplatin und Pemetrexed)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1346/","note":"Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, nicht-plattenepithelial, EGFR-, ALK- und ROS-negativ, Erstlinie, Kombination mit Carboplatin und Pemetrexed"},{"body":"G-BA","country":"Germany","drugId":"serplulimab","product":"Serplulimab","brand":"Hetronifly","title":"Serplulimab (Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, plattenepithelial, Erstlinie, Kombination mit Carboplatin und Nab-Paclitaxel)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1389/","note":"Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, plattenepithelial, Erstlinie, Kombination mit Carboplatin und Nab-Paclitaxel"},{"body":"G-BA","country":"Germany","drugId":"serplulimab","product":"Serplulimab","brand":"Hetronifly","title":"Serplulimab (Neues Anwendungsgebiet: Plattenepithelkarzinom des Ösophagus, PD-L1 mit CPS ≥ 5, Erstlinie, Kombination mit einer Fluoropyrimidin- und platinbasierten Chemotherapie)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1347/","note":"Neues Anwendungsgebiet: Plattenepithelkarzinom des Ösophagus, PD-L1 mit CPS ≥ 5, Erstlinie, Kombination mit einer Fluoropyrimidin- und platinbasierten Chemotherapie"},{"body":"G-BA","country":"Germany","drugId":"encorafenib","product":"Encorafenib","brand":"Braftovi","title":"Encorafenib (Neues Anwendungsgebiet: Kolorektalkarzinom mit BRAF-V600E-Mutation; Erstlinie; Kombination mit Cetuximab und FOLFOX)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-07-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1382/","note":"Neues Anwendungsgebiet: Kolorektalkarzinom mit BRAF-V600E-Mutation; Erstlinie; Kombination mit Cetuximab und FOLFOX"},{"body":"G-BA","country":"Germany","drugId":"epcoritamab","product":"Epcoritamab","brand":"Tepkinly","title":"Epcoritamab (Neues Anwendungsgebiet: Follikuläres Lymphom, rezidiviert oder refraktär, in Kombination mit Lenalidomid und Rituximab)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-07-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1379/","note":"Neues Anwendungsgebiet: Follikuläres Lymphom, rezidiviert oder refraktär, in Kombination mit Lenalidomid und Rituximab"},{"body":"G-BA","country":"Germany","drugId":"lurbinectedin","product":"Lurbinectedin","brand":"Zepzelca","title":"Lurbinectedin (Kleinzelliges Lungenkarzinom, extensives Stadium, Erhaltungstherapie, Kombination mit Atezolizumab)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-07-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1369/","note":"Kleinzelliges Lungenkarzinom, extensives Stadium, Erhaltungstherapie, Kombination mit Atezolizumab"},{"body":"G-BA","country":"Germany","drugId":"tarlatamab","product":"Tarlatamab","brand":"Imdylltra","title":"Tarlatamab (fortgeschrittenes kleinzelliges Lungenkarzinom, vorbehandelt)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-07-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1367/","note":"fortgeschrittenes kleinzelliges Lungenkarzinom, vorbehandelt"},{"body":"G-BA","country":"Germany","drugId":"venetoclax","product":"Venetoclax","brand":"Venclyxto","title":"Venetoclax (Neues Anwendungsgebiet: chronische lymphatische Leukämie, Erstlinie, Kombination mit Acalabrutinib mit oder ohne Obinutuzumab)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-07-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1376/","note":"Neues Anwendungsgebiet: chronische lymphatische Leukämie, Erstlinie, Kombination mit Acalabrutinib mit oder ohne Obinutuzumab"},{"body":"G-BA","country":"Germany","drugId":"venetoclax","product":"Venetoclax","brand":"Venclyxto","title":"Venetoclax (Neues Anwendungsgebiet: Chronische lymphatische Leukämie, Erstlinie, Kombination mit Ibrutinib)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-07-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1370/","note":"Neues Anwendungsgebiet: Chronische lymphatische Leukämie, Erstlinie, Kombination mit Ibrutinib"},{"body":"PBAC","country":"Australia","product":"All items considered at the meeting","title":"Recommendations made by the PBAC – July 2026","verdict":"document","verdictLabel":"Outcomes document","date":"2026-07","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-july-2026","documentUrl":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2026-07/pbac-web-outcomes-07-2026-v1.pdf","note":"PBAC publishes outcomes as PDF; open the document for product-level recommendations."},{"body":"G-BA","country":"Germany","drugId":"selpercatinib","product":"Selpercatinib","brand":"Retsevmo","title":"Selpercatinib (Neues Anwendungsgebiet: RET-mutiertes medulläres Schilddrüsenkarzinom (MTC), ≥ 2 Jahre)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-06-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1362/","note":"Neues Anwendungsgebiet: RET-mutiertes medulläres Schilddrüsenkarzinom (MTC), ≥ 2 Jahre"},{"body":"G-BA","country":"Germany","drugId":"selpercatinib","product":"Selpercatinib","brand":"Retsevmo","title":"Selpercatinib (Neues Anwendungsgebiet: Schilddrüsenkarzinom, RET-Fusions+, refraktär für radioaktives Iod, ≥ 2 Jahre)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-06-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1364/","note":"Neues Anwendungsgebiet: Schilddrüsenkarzinom, RET-Fusions+, refraktär für radioaktives Iod, ≥ 2 Jahre"},{"body":"G-BA","country":"Germany","drugId":"selpercatinib","product":"Selpercatinib","brand":"Retsevmo","title":"Selpercatinib (Neues Anwendungsgebiet: Solide Tumore, RET-Fusion+, ≥ 2 bis < 18 Jahre)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-06-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1363/","note":"Neues Anwendungsgebiet: Solide Tumore, RET-Fusion+, ≥ 2 bis < 18 Jahre"},{"body":"G-BA","country":"Germany","drugId":"asciminib","product":"Asciminib","brand":"Scemblix","title":"Asciminib (Neues Anwendungsgebiet: Chronische myeloische Leukämie, Ph+, CML-CP mit T315I-Mutation, vorbehandelt)","verdict":"Stellungnahmeverfahren eröffnet","verdictLabel":"Stellungnahmeverfahren eröffnet","date":"2026-06-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1344/","note":"Neues Anwendungsgebiet: Chronische myeloische Leukämie, Ph+, CML-CP mit T315I-Mutation, vorbehandelt"},{"body":"G-BA","country":"Germany","drugId":"blinatumomab","product":"Blinatumomab","brand":"Blincyto","title":"Blinatumomab (Neubewertung Orphan > 30 Mio: Akute lymphatische B-​Zell-Leukämie, CD19+, rezidiviert oder refraktär, Erwachsene)","verdict":"Stellungnahmeverfahren eröffnet","verdictLabel":"Stellungnahmeverfahren eröffnet","date":"2026-06-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1345/","note":"Neubewertung Orphan > 30 Mio: Akute lymphatische B-​Zell-Leukämie, CD19+, rezidiviert oder refraktär, Erwachsene"},{"body":"G-BA","country":"Germany","drugId":"blinatumomab","product":"Blinatumomab","brand":"Blincyto","title":"Blinatumomab (Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, Hochrisiko-Erstrezidiv, Kinder ab ≥1 Monat)","verdict":"Stellungnahmeverfahren eröffnet","verdictLabel":"Stellungnahmeverfahren eröffnet","date":"2026-06-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1351/","note":"Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, Hochrisiko-Erstrezidiv, Kinder ab ≥1 Monat"},{"body":"G-BA","country":"Germany","drugId":"blinatumomab","product":"Blinatumomab","brand":"Blincyto","title":"Blinatumomab (Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, MRD-positiv, Erwachsene)","verdict":"Stellungnahmeverfahren eröffnet","verdictLabel":"Stellungnahmeverfahren eröffnet","date":"2026-06-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1349/","note":"Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, MRD-positiv, Erwachsene"},{"body":"G-BA","country":"Germany","drugId":"blinatumomab","product":"Blinatumomab","brand":"Blincyto","title":"Blinatumomab (Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, neu diagnostiziert, Erwachsene)","verdict":"Stellungnahmeverfahren eröffnet","verdictLabel":"Stellungnahmeverfahren eröffnet","date":"2026-06-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1354/","note":"Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, neu diagnostiziert, Erwachsene"},{"body":"G-BA","country":"Germany","drugId":"blinatumomab","product":"Blinatumomab","brand":"Blincyto","title":"Blinatumomab (Neubewertung Orphan > 30 Mio: Akute lymphatische B-​Zell-Leukämie, Ph-, CD19+, rezidiviert / refraktär, nach ≥ 2 Vortherapien oder nach allogener Stammzelltransplantation, Kinder ≥ 1 Monat)","verdict":"Stellungnahmeverfahren eröffnet","verdictLabel":"Stellungnahmeverfahren eröffnet","date":"2026-06-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1348/","note":"Neubewertung Orphan > 30 Mio: Akute lymphatische B-​Zell-Leukämie, Ph-, CD19+, rezidiviert / refraktär, nach ≥ 2 Vortherapien oder nach allogener Stammzelltransplantation, Kinder ≥ 1 Monat"},{"body":"G-BA","country":"Germany","drugId":"inotuzumab-ozogamicin","product":"Inotuzumab ozogamicin","brand":"Besponsa","title":"Inotuzumab ozogamicin (Neues Anwendungsgebiet: akute lymphatische Vorläufer B-Zell-Leukämie, rezidiviert/refraktär, nach allogener Stammzelltransplantation oder nach Rezidiv mit sehr hohem Risiko oder nach ≥ 2 Vortherapien, CD22+, pädiatrische Patienten ≥ 1 Jahr)","verdict":"Stellungnahmeverfahren eröffnet","verdictLabel":"Stellungnahmeverfahren eröffnet","date":"2026-06-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1358/","note":"Neues Anwendungsgebiet: akute lymphatische Vorläufer B-Zell-Leukämie, rezidiviert/refraktär, nach allogener Stammzelltransplantation oder nach Rezidiv mit sehr hohem Risiko oder nach ≥ 2 Vortherapien, CD22+, pädiatrische Patienten ≥ 1 Jahr"},{"body":"G-BA","country":"Germany","drugId":"relatlimab-nivolumab","product":"Relatlimab + nivolumab","brand":"Opdualag","title":"Nivolumab/Relatlimab (Melanom, PD-L1-Expression < 1 %, fortgeschritten, Erstlinie, ≥ 12 Jahre)","verdict":"Stellungnahmeverfahren eröffnet","verdictLabel":"Stellungnahmeverfahren eröffnet","date":"2026-06-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1335/","note":"Melanom, PD-L1-Expression < 1 %, fortgeschritten, Erstlinie, ≥ 12 Jahre"},{"body":"G-BA","country":"Germany","drugId":"tovorafenib","product":"Tovorafenib","brand":"Ojemda","title":"Tovorafenib (Malignes Gliom, niedrig-gradig mit BRAF-Fusion oder -Umlagerung oder BRAF-V600-Mutation, nach mind. 1 Vortherapie, ≥ 6 Monate)","verdict":"Beschlussfassung wird vorbereitet","verdictLabel":"Beschlussfassung wird vorbereitet","date":"2026-05-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1342/","note":"Malignes Gliom, niedrig-gradig mit BRAF-Fusion oder -Umlagerung oder BRAF-V600-Mutation, nach mind. 1 Vortherapie, ≥ 6 Monate"},{"body":"G-BA","country":"Germany","drugId":"zolbetuximab","product":"Zolbetuximab","brand":"Vyloy","title":"Zolbetuximab (Neubewertung Orphan > 30 Mio: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, HER2-negativ, Erstlinie, Kombination mit fluoropyrimidin- und platinhaltiger Chemotherapie)","verdict":"Beschlussfassung wird vorbereitet","verdictLabel":"Beschlussfassung wird vorbereitet","date":"2026-05-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1343/","note":"Neubewertung Orphan > 30 Mio: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, HER2-negativ, Erstlinie, Kombination mit fluoropyrimidin- und platinhaltiger Chemotherapie"},{"body":"G-BA","country":"Germany","drugId":"belumosudil","product":"Belumosudil","brand":"Rezurock","title":"Belumosudil (Chronische Graft-versus-Host-Erkrankung (cGvHD), ≥ 12 Jahre, ≥ 40 kg)","verdict":"Beschlussfassung wird vorbereitet","verdictLabel":"Beschlussfassung wird vorbereitet","date":"2026-05-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1338/","note":"Chronische Graft-versus-Host-Erkrankung (cGvHD), ≥ 12 Jahre, ≥ 40 kg"},{"body":"PBAC","country":"Australia","product":"All items considered at the meeting","title":"Recommendations made by the PBAC – May 2026 Intracycle meeting","verdict":"document","verdictLabel":"Outcomes document","date":"2026-05","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-may-2026-intracycle-meeting","documentUrl":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2026-05/pbac-web-outcomes-05-2026.pdf","note":"PBAC publishes outcomes as PDF; open the document for product-level recommendations."},{"body":"G-BA","country":"Germany","drugId":"belantamab-mafodotin","product":"Belantamab mafodotin","brand":"Blenrep","title":"Belantamab-Mafodotin (Multiples Myelom, rezidiviert oder refraktär, nach mind. einer Vortherapie, Kombination mit Bortezomib und Dexamethason)","verdict":"Beschlussfassung wird vorbereitet","verdictLabel":"Beschlussfassung wird vorbereitet","date":"2026-04-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1328/","note":"Multiples Myelom, rezidiviert oder refraktär, nach mind. einer Vortherapie, Kombination mit Bortezomib und Dexamethason"},{"body":"G-BA","country":"Germany","drugId":"belantamab-mafodotin","product":"Belantamab mafodotin","brand":"Blenrep","title":"Belantamab-Mafodotin (Multiples Myelom, rezidiviert oder refraktär, nach mind. einer Vortherapie, Kombination mit Pomalidomid und Dexamethason)","verdict":"Beschlussfassung wird vorbereitet","verdictLabel":"Beschlussfassung wird vorbereitet","date":"2026-04-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1330/","note":"Multiples Myelom, rezidiviert oder refraktär, nach mind. einer Vortherapie, Kombination mit Pomalidomid und Dexamethason"},{"body":"G-BA","country":"Germany","drugId":"retifanlimab","product":"Retifanlimab","brand":"Zynyz","title":"Retifanlimab (Merkelzellkarzinom, metastasiert oder rezidiviert, Monotherapie, Erstlinie)","verdict":"Beschlussfassung wird vorbereitet","verdictLabel":"Beschlussfassung wird vorbereitet","date":"2026-04-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1319/","note":"Merkelzellkarzinom, metastasiert oder rezidiviert, Monotherapie, Erstlinie"},{"body":"G-BA","country":"Germany","drugId":"retifanlimab","product":"Retifanlimab","brand":"Zynyz","title":"Retifanlimab (Neues Anwendungsgebiet: Plattenepithelkarzinom des Analkanals; Erstlinie)","verdict":"Beschlussfassung wird vorbereitet","verdictLabel":"Beschlussfassung wird vorbereitet","date":"2026-04-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1334/","note":"Neues Anwendungsgebiet: Plattenepithelkarzinom des Analkanals; Erstlinie"},{"body":"G-BA","country":"Germany","drugId":"imlunestrant","product":"Imlunestrant","brand":"Inluriyo","title":"Imlunestrant (Mammakarzinom, ER+, HER2-, mit ESR1-Mutation, progredient nach einer endokrinen Vortherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2026-03-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1326/","note":"Mammakarzinom, ER+, HER2-, mit ESR1-Mutation, progredient nach einer endokrinen Vortherapie"},{"body":"G-BA","country":"Germany","drugId":"niraparib","product":"Niraparib","brand":"Akeega","title":"Niraparib/Abirateronacetat (Neues Anwendungsgebiet: Prostatakarzinom, metastasiert, hormonsensitiv, BRCA1/2-Mutationen, Kombination mit Prednis(ol)on und Androgendeprivationstherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2026-03-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1327/","note":"Neues Anwendungsgebiet: Prostatakarzinom, metastasiert, hormonsensitiv, BRCA1/2-Mutationen, Kombination mit Prednis(ol)on und Androgendeprivationstherapie"},{"body":"G-BA","country":"Germany","drugId":"abemaciclib","product":"Abemaciclib","brand":"Verzenios","title":"Abemaciclib (Neubewertung nach Fristablauf: Mammakarzinom, HR+, HER2-, früh mit hohem Rezidivrisiko, Adjuvanz, Kombination mit endokriner Therapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2026-03-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1320/","note":"Neubewertung nach Fristablauf: Mammakarzinom, HR+, HER2-, früh mit hohem Rezidivrisiko, Adjuvanz, Kombination mit endokriner Therapie"},{"body":"G-BA","country":"Germany","drugId":"ivosidenib","product":"Ivosidenib","brand":"Tibsovo","title":"Ivosidenib (Neubewertung Orphan > 30 Mio: Akute Myeloische Leukämie mit IDH1-R132-Mutation, Erstlinie, Kombination mit Azacitidin)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2026-03-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1321/","note":"Neubewertung Orphan > 30 Mio: Akute Myeloische Leukämie mit IDH1-R132-Mutation, Erstlinie, Kombination mit Azacitidin"},{"body":"G-BA","country":"Germany","drugId":"ivosidenib","product":"Ivosidenib","brand":"Tibsovo","title":"Ivosidenib (Neubewertung Orphan > 30 Mio: Cholangiokarzinom mit IDH1-R132-Mutation, nach mind. 1 Vortherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2026-03-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1322/","note":"Neubewertung Orphan > 30 Mio: Cholangiokarzinom mit IDH1-R132-Mutation, nach mind. 1 Vortherapie"},{"body":"PBAC","country":"Australia","product":"All items considered at the meeting","title":"Recommendations made by the PBAC – March 2026","verdict":"document","verdictLabel":"Outcomes document","date":"2026-03","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-march-2026","documentUrl":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2026-03/pbac-web-outcomes-03-2026-v3.pdf","note":"PBAC publishes outcomes as PDF; open the document for product-level recommendations."},{"body":"G-BA","country":"Germany","drugId":"zanidatamab","product":"Zanidatamab","brand":"Ziihera","title":"Zanidatamab (Biliäres Karzinom, HER2+ (IHC3+), vorbehandelt)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2026-02-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1312/","note":"Biliäres Karzinom, HER2+ (IHC3+), vorbehandelt"},{"body":"G-BA","country":"Germany","drugId":"mirvetuximab-soravtansine","product":"Mirvetuximab soravtansine","brand":"Elahere","title":"Mirvetuximab-Soravtansin (Neubewertung Orphan > 30 Mio: Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom, FRα-positiv, platinresistent, nach 1 bis 3 Vortherapien)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2026-02-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1305/","note":"Neubewertung Orphan > 30 Mio: Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom, FRα-positiv, platinresistent, nach 1 bis 3 Vortherapien"},{"body":"G-BA","country":"Germany","drugId":"tafasitamab","product":"Tafasitamab","brand":"Minjuvi","title":"Tafasitamab (Neues Anwendungsgebiet: Follikuläres Lymphom, nach ≥ 1 Vortherapie, Kombination mit Lenalidomid und Rituximab)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2026-01-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1302/","note":"Neues Anwendungsgebiet: Follikuläres Lymphom, nach ≥ 1 Vortherapie, Kombination mit Lenalidomid und Rituximab"},{"body":"G-BA","country":"Germany","drugId":"toripalimab","product":"Toripalimab","brand":"Loqtorzi","title":"Toripalimab (Plattenepithelkarzinom des Ösophagus, Erstlinie, Kombination mit Cisplatin und Paclitaxel)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2026-01-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1303/","note":"Plattenepithelkarzinom des Ösophagus, Erstlinie, Kombination mit Cisplatin und Paclitaxel"},{"body":"G-BA","country":"Germany","drugId":"toripalimab","product":"Toripalimab","brand":"Loqtorzi","title":"Toripalimab (Rezidiviertes oder metastasiertes Nasopharynxkarzinom (NPC), Erstlinie, Kombination mit Cisplatin und Gemcitabin)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2026-01-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1304/","note":"Rezidiviertes oder metastasiertes Nasopharynxkarzinom (NPC), Erstlinie, Kombination mit Cisplatin und Gemcitabin"},{"body":"G-BA","country":"Germany","drugId":"selpercatinib","product":"Selpercatinib","brand":"Retsevmo","title":"Selpercatinib (Neubewertung nach Fristablauf: Nicht-kleinzelliges Lungenkarzinom, RET-Fusion+, Erstlinie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2026-01-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1301/","note":"Neubewertung nach Fristablauf: Nicht-kleinzelliges Lungenkarzinom, RET-Fusion+, Erstlinie"},{"body":"G-BA","country":"Germany","drugId":"cemiplimab","product":"Cemiplimab","brand":"Libtayo","title":"Cemiplimab (Neues Anwendungsgebiet: kutanes Plattenepithelkarzinom, nach Resektion und Strahlentherapie, adjuvante Therapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-12-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1293/","note":"Neues Anwendungsgebiet: kutanes Plattenepithelkarzinom, nach Resektion und Strahlentherapie, adjuvante Therapie"},{"body":"G-BA","country":"Germany","drugId":"lisocabtagene-maraleucel","product":"Lisocabtagene maraleucel","brand":"Breyanzi","title":"Lisocabtagen maraleucel (Neues Anwendungsgebiet: Mantelzell-Lymphom, nach ≥ 2 Vortherapien)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-12-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1295/","note":"Neues Anwendungsgebiet: Mantelzell-Lymphom, nach ≥ 2 Vortherapien"},{"body":"G-BA","country":"Germany","drugId":"nivolumab","product":"Nivolumab","brand":"Opdivo","title":"Nivolumab (Neubewertung nach Fristablauf: Urothelkarzinom, PD-L1-Expression ≥ 1 %, adjuvante Therapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-12-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1294/","note":"Neubewertung nach Fristablauf: Urothelkarzinom, PD-L1-Expression ≥ 1 %, adjuvante Therapie"},{"body":"G-BA","country":"Germany","drugId":"asciminib","product":"Asciminib","brand":"Scemblix","title":"Asciminib (Neues Anwendungsgebiet: Chronische myeloische Leukämie, Ph+, chronische Phase)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-12-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1287/","note":"Neues Anwendungsgebiet: Chronische myeloische Leukämie, Ph+, chronische Phase"},{"body":"G-BA","country":"Germany","drugId":"pembrolizumab","product":"Pembrolizumab","brand":"Keytruda","title":"Pembrolizumab (Neues Anwendungsgebiet: Resezierbares lokal fortgeschrittenes Plattenepithelkarzinom der Kopf-Hals-Region, PD-L1-Expression ≥ 1 %, neoadjuvante und adjuvante Therapie, Kombination mit Strahlentherapie mit oder ohne begleitende Cisplatin-Therapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-12-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1288/","note":"Neues Anwendungsgebiet: Resezierbares lokal fortgeschrittenes Plattenepithelkarzinom der Kopf-Hals-Region, PD-L1-Expression ≥ 1 %, neoadjuvante und adjuvante Therapie, Kombination mit Strahlentherapie mit oder ohne begleitende Cisplatin-Therapie"},{"body":"PBAC","country":"Australia","product":"All items considered at the meeting","title":"Recommendations made by the PBAC – December 2025 Intracycle Meeting","verdict":"document","verdictLabel":"Outcomes document","date":"2025-12","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-december-2025-intracycle-meeting","documentUrl":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2025-12/pbac-web-outcomes-v2-12-2025.pdf","note":"PBAC publishes outcomes as PDF; open the document for product-level recommendations."},{"body":"G-BA","country":"Germany","drugId":"vorasidenib","product":"Vorasidenib","brand":"Voranigo","title":"Vorasidenib (Astrozytom oder Oligodendrogliom, Grad 2, IDH1-R132- oder IDH2-R172-Mutation, nach chirurgischer Intervention, ≥ 12 Jahre ≥ 40 kg)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-11-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1282/","note":"Astrozytom oder Oligodendrogliom, Grad 2, IDH1-R132- oder IDH2-R172-Mutation, nach chirurgischer Intervention, ≥ 12 Jahre ≥ 40 kg"},{"body":"G-BA","country":"Germany","drugId":"avapritinib","product":"Avapritinib","brand":"Ayvakyt","title":"Avapritinib (Neubewertung Orphan > 30 Mio: fortgeschrittene systemische Mastozytose, nach mind. 1 Vortherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-11-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1273/","note":"Neubewertung Orphan > 30 Mio: fortgeschrittene systemische Mastozytose, nach mind. 1 Vortherapie"},{"body":"G-BA","country":"Germany","drugId":"avapritinib","product":"Avapritinib","brand":"Ayvakyt","title":"Avapritinib (Neubewertung Orphan > 30 Mio: Gastrointestinale Stromatumoren)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-11-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1276/","note":"Neubewertung Orphan > 30 Mio: Gastrointestinale Stromatumoren"},{"body":"G-BA","country":"Germany","drugId":"avapritinib","product":"Avapritinib","brand":"Ayvakyt","title":"Avapritinib (Neubewertung Orphan > 30 Mio: Indolente systemische Mastozytose (ISM))","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-11-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1275/","note":"Neubewertung Orphan > 30 Mio: Indolente systemische Mastozytose (ISM)"},{"body":"G-BA","country":"Germany","drugId":"momelotinib","product":"Momelotinib","brand":"Omjjara","title":"Momelotinib (Neubewertung Orphan > 30 Mio: Myelofibrose)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-11-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1277/","note":"Neubewertung Orphan > 30 Mio: Myelofibrose"},{"body":"G-BA","country":"Germany","drugId":"vimseltinib","product":"Vimseltinib","brand":"Romvimza","title":"Vimseltinib (Symptomatische tenosynoviale Riesenzelltumoren)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-11-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1274/","note":"Symptomatische tenosynoviale Riesenzelltumoren"},{"body":"PBAC","country":"Australia","product":"All items considered at the meeting","title":"Recommendations made by the PBAC – November 2025","verdict":"document","verdictLabel":"Outcomes document","date":"2025-11","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-november-2025","documentUrl":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2025-11/pbac-web-outcomes-11-2025-v2.pdf","note":"PBAC publishes outcomes as PDF; open the document for product-level recommendations."},{"body":"G-BA","country":"Germany","drugId":"nirogacestat","product":"Nirogacestat","brand":"Ogsiveo","title":"Nirogacestat (Desmoid-Tumor, fortgeschritten)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-10-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1271/","note":"Desmoid-Tumor, fortgeschritten"},{"body":"G-BA","country":"Germany","drugId":"linvoseltamab","product":"Linvoseltamab","brand":"Lynozyfic","title":"Linvoseltamab (Multiples Myelom, mind. 3 Vortherapien, Monotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-10-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1269/","note":"Multiples Myelom, mind. 3 Vortherapien, Monotherapie"},{"body":"G-BA","country":"Germany","drugId":"tislelizumab","product":"Tislelizumab","brand":"Tevimbra","title":"Tislelizumab (Neues Anwendungsgebiet: Kleinzelliges Lungenkarzinom, Erstlinie, Kombination mit Etoposid und Platin-Chemotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-10-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1233/","note":"Neues Anwendungsgebiet: Kleinzelliges Lungenkarzinom, Erstlinie, Kombination mit Etoposid und Platin-Chemotherapie"},{"body":"G-BA","country":"Germany","drugId":"tislelizumab","product":"Tislelizumab","brand":"Tevimbra","title":"Tislelizumab (Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, hohes Rezidivrisiko, neoadjuvante und adjuvante Therapie, Monotherapie oder Kombination mit Platin-basierter Chemotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-10-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1267/","note":"Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, hohes Rezidivrisiko, neoadjuvante und adjuvante Therapie, Monotherapie oder Kombination mit Platin-basierter Chemotherapie"},{"body":"G-BA","country":"Germany","drugId":"tislelizumab","product":"Tislelizumab","brand":"Tevimbra","title":"Tislelizumab (Neues Anwendungsgebiet: rezidiviertes oder metastasiertes Nasopharynxkarzinom (NPC), Erstlinie, Kombination mit Gemcitabin and Cisplatin)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-10-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1254/","note":"Neues Anwendungsgebiet: rezidiviertes oder metastasiertes Nasopharynxkarzinom (NPC), Erstlinie, Kombination mit Gemcitabin and Cisplatin"},{"body":"G-BA","country":"Germany","drugId":"trastuzumab-deruxtecan","product":"Trastuzumab deruxtecan","brand":"Enhertu","title":"Trastuzumab deruxtecan (Neue wissenschaftliche Erkenntnisse § 14: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, HER2+, nach Trastuzumab-basierter Therapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-10-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1266/","note":"Neue wissenschaftliche Erkenntnisse § 14: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, HER2+, nach Trastuzumab-basierter Therapie"},{"body":"G-BA","country":"Germany","drugId":"tisotumab-vedotin","product":"Tisotumab vedotin","brand":"Tivdak","title":"Tisotumab vedotin (Zervixkarzinom, vorbehandelt)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-09-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1256/","note":"Zervixkarzinom, vorbehandelt"},{"body":"PBAC","country":"Australia","product":"All items considered at the meeting","title":"Recommendations made by the PBAC – September 2025 Intracycle meeting","verdict":"document","verdictLabel":"Outcomes document","date":"2025-09","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-september-2025","documentUrl":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2025-09/pbac-web-outcomes-09-2025v2.pdf","note":"PBAC publishes outcomes as PDF; open the document for product-level recommendations."},{"body":"G-BA","country":"Germany","drugId":"daratumumab","product":"Daratumumab","brand":"Darzalex","title":"Daratumumab (Neues Anwendungsgebiet: Multiples Myelom, Stammzelltransplantation ungeeignet, Kombination mit Bortezomib, Lenalidomid und Dexamethason)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-08-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1222/","note":"Neues Anwendungsgebiet: Multiples Myelom, Stammzelltransplantation ungeeignet, Kombination mit Bortezomib, Lenalidomid und Dexamethason"},{"body":"G-BA","country":"Germany","drugId":"daratumumab","product":"Daratumumab","brand":"Darzalex","title":"Daratumumab (Neues Anwendungsgebiet: schwelendes multiples Myelom (SMM))","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-08-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1255/","note":"Neues Anwendungsgebiet: schwelendes multiples Myelom (SMM)"},{"body":"G-BA","country":"Germany","drugId":"darolutamide","product":"Darolutamide","brand":"Nubeqa","title":"Darolutamid (Neues Anwendungsgebiet: Prostatakarzinom, metastasiert, hormonsensitiv, Kombination mit Androgendeprivationstherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-08-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1252/","note":"Neues Anwendungsgebiet: Prostatakarzinom, metastasiert, hormonsensitiv, Kombination mit Androgendeprivationstherapie"},{"body":"G-BA","country":"Germany","drugId":"inavolisib","product":"Inavolisib","brand":"Itovebi","title":"Inavolisib (Mammakarzinom, PIK3CA-mutiert, ER+, HER2-, lokal fortgeschritten oder metastasiert, Rezidiv < 12 Monate nach adjuvanter endokriner Therapie, Kombination mit Palbociclib und Fulvestrant)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-08-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1253/","note":"Mammakarzinom, PIK3CA-mutiert, ER+, HER2-, lokal fortgeschritten oder metastasiert, Rezidiv < 12 Monate nach adjuvanter endokriner Therapie, Kombination mit Palbociclib und Fulvestrant"},{"body":"G-BA","country":"Germany","drugId":"isatuximab","product":"Isatuximab","brand":"Sarclisa","title":"Isatuximab (Neues Anwendungsgebiet: Multiples Myelom, Erstlinie, Stammzelltransplantation geeignet, Kombination mit Bortezomib, Lenalidomid und Dexamethason)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-08-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1251/","note":"Neues Anwendungsgebiet: Multiples Myelom, Erstlinie, Stammzelltransplantation geeignet, Kombination mit Bortezomib, Lenalidomid und Dexamethason"},{"body":"G-BA","country":"Germany","drugId":"durvalumab","product":"Durvalumab","brand":"Imfinzi","title":"Durvalumab (Neues Anwendungsgebiet: kleinzelliges Lungenkarzinom, nicht fortgeschrittenes Stadium, nach platinbasierter Radiochemotherapie, Monotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1201/","note":"Neues Anwendungsgebiet: kleinzelliges Lungenkarzinom, nicht fortgeschrittenes Stadium, nach platinbasierter Radiochemotherapie, Monotherapie"},{"body":"G-BA","country":"Germany","drugId":"durvalumab","product":"Durvalumab","brand":"Imfinzi","title":"Durvalumab (Neues Anwendungsgebiet: Muskelinvasives Blasenkarzinom (MIBC), neoadjuvante/adjuvante Therapie nach Zystektomie, Kombination mit Gemcitabin und Cisplatin)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1247/","note":"Neues Anwendungsgebiet: Muskelinvasives Blasenkarzinom (MIBC), neoadjuvante/adjuvante Therapie nach Zystektomie, Kombination mit Gemcitabin und Cisplatin"},{"body":"G-BA","country":"Germany","drugId":"durvalumab","product":"Durvalumab","brand":"Imfinzi","title":"Durvalumab (Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, EGFR/ALK-negativ, neoadjuvante/adjuvante Therapie, Kombination mit platinbasierter Chemotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1207/","note":"Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, EGFR/ALK-negativ, neoadjuvante/adjuvante Therapie, Kombination mit platinbasierter Chemotherapie"},{"body":"G-BA","country":"Germany","drugId":"odronextamab","product":"Odronextamab","brand":"Ordspono","title":"Odronextamab (Diffus großzelliges B-Zell-Lymphom (DLBCL), nach ≥ 2 Vortherapien)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1248/","note":"Diffus großzelliges B-Zell-Lymphom (DLBCL), nach ≥ 2 Vortherapien"},{"body":"G-BA","country":"Germany","drugId":"odronextamab","product":"Odronextamab","brand":"Ordspono","title":"Odronextamab (follikuläres Lymphom, nach ≥ 2 Vortherapien)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1249/","note":"follikuläres Lymphom, nach ≥ 2 Vortherapien"},{"body":"G-BA","country":"Germany","drugId":"acalabrutinib","product":"Acalabrutinib","brand":"Calquence","title":"Acalabrutinib (Neues Anwendungsgebiet: Chronische lymphatische Leukämie, Erstlinie, Kombination mit Venetoclax)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-07-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1238/","note":"Neues Anwendungsgebiet: Chronische lymphatische Leukämie, Erstlinie, Kombination mit Venetoclax"},{"body":"G-BA","country":"Germany","drugId":"acalabrutinib","product":"Acalabrutinib","brand":"Calquence","title":"Acalabrutinib (Neues Anwendungsgebiet: Chronische lymphatische Leukämie, Erstlinie, Kombination mit Venetoclax und Obinutuzumab)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-07-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1239/","note":"Neues Anwendungsgebiet: Chronische lymphatische Leukämie, Erstlinie, Kombination mit Venetoclax und Obinutuzumab"},{"body":"G-BA","country":"Germany","drugId":"acalabrutinib","product":"Acalabrutinib","brand":"Calquence","title":"Acalabrutinib (Neues Anwendungsgebiet: Mantelzell-Lymphom, autologe Stammzelltransplantation ungeeignet, Erstlinie, Kombination mit Bendamustin und Rituximab)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-07-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1234/","note":"Neues Anwendungsgebiet: Mantelzell-Lymphom, autologe Stammzelltransplantation ungeeignet, Erstlinie, Kombination mit Bendamustin und Rituximab"},{"body":"G-BA","country":"Germany","drugId":"acalabrutinib","product":"Acalabrutinib","brand":"Calquence","title":"Acalabrutinib (Neues Anwendungsgebiet: Mantelzell-Lymphom, keine BTKi Vortherapie, rezidiviert oder refraktär, Monotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-07-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1235/","note":"Neues Anwendungsgebiet: Mantelzell-Lymphom, keine BTKi Vortherapie, rezidiviert oder refraktär, Monotherapie"},{"body":"G-BA","country":"Germany","drugId":"nivolumab","product":"Nivolumab","brand":"Opdivo","title":"Nivolumab (Neubewertung nach Fristablauf: Karzinom des Ösophagus oder gastroösophagealen Übergangs, vorbehandelte Patienten, adjuvante Therapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-07-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1240/","note":"Neubewertung nach Fristablauf: Karzinom des Ösophagus oder gastroösophagealen Übergangs, vorbehandelte Patienten, adjuvante Therapie"},{"body":"G-BA","country":"Germany","drugId":"nivolumab","product":"Nivolumab","brand":"Opdivo","title":"Nivolumab (Neues Anwendungsgebiet: Kolorektalkarzinom mit MSI-H oder mit dMMR, Erstlinie, Kombination mit Ipilimumab)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-06-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1170/","note":"Neues Anwendungsgebiet: Kolorektalkarzinom mit MSI-H oder mit dMMR, Erstlinie, Kombination mit Ipilimumab"},{"body":"G-BA","country":"Germany","drugId":"nivolumab","product":"Nivolumab","brand":"Opdivo","title":"Nivolumab (Neues Anwendungsgebiet: nicht resezierbares oder fortgeschrittenes Leberzellkarzinom, Erstlinie, Kombination mit Ipilimumab)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-06-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1197/","note":"Neues Anwendungsgebiet: nicht resezierbares oder fortgeschrittenes Leberzellkarzinom, Erstlinie, Kombination mit Ipilimumab"},{"body":"G-BA","country":"Germany","drugId":"nivolumab","product":"Nivolumab","brand":"Opdivo","title":"Nivolumab (Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, PD-L1-Expression ≥ 1 %, neoadjuvante und adjuvante Therapie, Monotherapie oder Kombination mit Platin-basierter Chemotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-06-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1232/","note":"Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, PD-L1-Expression ≥ 1 %, neoadjuvante und adjuvante Therapie, Monotherapie oder Kombination mit Platin-basierter Chemotherapie"},{"body":"G-BA","country":"Germany","drugId":"asciminib","product":"Asciminib","brand":"Scemblix","title":"Asciminib (Neubewertung Orphan > 30 Mio: Chronische myeloische Leukämie, Ph+, nach ≥ 2 Vortherapien)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-06-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1225/","note":"Neubewertung Orphan > 30 Mio: Chronische myeloische Leukämie, Ph+, nach ≥ 2 Vortherapien"},{"body":"G-BA","country":"Germany","drugId":"datopotamab-deruxtecan","product":"Datopotamab deruxtecan","brand":"Datroway","title":"Datopotamab deruxtecan (Mammakarzinom, HR+, HER2-, nach min. 1 Vortherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-06-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1224/","note":"Mammakarzinom, HR+, HER2-, nach min. 1 Vortherapie"},{"body":"G-BA","country":"Germany","drugId":"selpercatinib","product":"Selpercatinib","brand":"Retsevmo","title":"Selpercatinib (Neubewertung nach Fristablauf: Schilddrüsenkarzinom, RET-mutiert, Monotherapie, ab 12 Jahren)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-06-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1223/","note":"Neubewertung nach Fristablauf: Schilddrüsenkarzinom, RET-mutiert, Monotherapie, ab 12 Jahren"},{"body":"G-BA","country":"Germany","drugId":"glofitamab","product":"Glofitamab","brand":"Columvi","title":"Glofitamab (Aufhebung des regulatorischen Orphanstatus: Diffus großzelliges B-Zell-Lymphom (DLBCL), nach ≥ 2 Vortherapien)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-05-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1221/","note":"Aufhebung des regulatorischen Orphanstatus: Diffus großzelliges B-Zell-Lymphom (DLBCL), nach ≥ 2 Vortherapien"},{"body":"G-BA","country":"Germany","drugId":"glofitamab","product":"Glofitamab","brand":"Columvi","title":"Glofitamab (Neues Anwendungsgebiet: Diffuses großzelliges B-Zell-Lymphom, rezidiviert oder refraktär, Kombination mit Gemcitabin und Oxaliplatin, autologe Stammzelltransplantation nicht geeignet)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-05-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1220/","note":"Neues Anwendungsgebiet: Diffuses großzelliges B-Zell-Lymphom, rezidiviert oder refraktär, Kombination mit Gemcitabin und Oxaliplatin, autologe Stammzelltransplantation nicht geeignet"},{"body":"G-BA","country":"Germany","drugId":"bevacizumab","product":"Bevacizumab","brand":"Lytenava","title":"Bevacizumab (Bekannter Wirkstoff mit neuem Unterlagenschutz: Neovaskuläre altersabhängige Makuladegeneration)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-05-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1212/","note":"Bekannter Wirkstoff mit neuem Unterlagenschutz: Neovaskuläre altersabhängige Makuladegeneration"},{"body":"G-BA","country":"Germany","drugId":"pembrolizumab","product":"Pembrolizumab","brand":"Keytruda","title":"Pembrolizumab (Neues Anwendungsgebiet: Malignes Pleuramesotheliom, nicht-epitheloid, Erstlinie, Kombination mit Pemetrexed und Platin-Chemotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-05-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1203/","note":"Neues Anwendungsgebiet: Malignes Pleuramesotheliom, nicht-epitheloid, Erstlinie, Kombination mit Pemetrexed und Platin-Chemotherapie"},{"body":"G-BA","country":"Germany","drugId":"repotrectinib","product":"Repotrectinib","brand":"Augtyro","title":"Repotrectinib (Nicht-kleinzelliges Lungenkarzinom, ROS1-positiv)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-05-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1205/","note":"Nicht-kleinzelliges Lungenkarzinom, ROS1-positiv"},{"body":"G-BA","country":"Germany","drugId":"repotrectinib","product":"Repotrectinib","brand":"Augtyro","title":"Repotrectinib (Solide Tumore, NTRK-Genfusion, ≥ 12 Jahre)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-05-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1204/","note":"Solide Tumore, NTRK-Genfusion, ≥ 12 Jahre"},{"body":"G-BA","country":"Germany","drugId":"serplulimab","product":"Serplulimab","brand":"Hetronifly","title":"Serplulimab (kleinzelliges Lungenkarzinom, in Kombination mit Carboplatin und Etoposid, Erstlinie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-05-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1206/","note":"kleinzelliges Lungenkarzinom, in Kombination mit Carboplatin und Etoposid, Erstlinie"},{"body":"G-BA","country":"Germany","drugId":"trastuzumab-deruxtecan","product":"Trastuzumab deruxtecan","brand":"Enhertu","title":"Trastuzumab deruxtecan (Neues Anwendungsgebiet: Mammakarzinom, HR+, HER2-low oder -ultralow, nach mind. 1 endokrinen Therapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-05-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1202/","note":"Neues Anwendungsgebiet: Mammakarzinom, HR+, HER2-low oder -ultralow, nach mind. 1 endokrinen Therapie"},{"body":"G-BA","country":"Germany","drugId":"lisocabtagene-maraleucel","product":"Lisocabtagene maraleucel","brand":"Breyanzi","title":"Lisocabtagen maraleucel (Neues Anwendungsgebiet: follikuläres Lymphom, nach ≥ 2 Vortherapien)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-04-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1200/","note":"Neues Anwendungsgebiet: follikuläres Lymphom, nach ≥ 2 Vortherapien"},{"body":"G-BA","country":"Germany","drugId":"pirtobrutinib","product":"Pirtobrutinib","brand":"Jaypirca","title":"Pirtobrutinib (Neues Anwendungsgebiet: Chronische lymphatische Leukämie (CLL), rezidiviert oder refraktär, Monotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-04-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1199/","note":"Neues Anwendungsgebiet: Chronische lymphatische Leukämie (CLL), rezidiviert oder refraktär, Monotherapie"},{"body":"G-BA","country":"Germany","drugId":"belzutifan","product":"Belzutifan","brand":"Welireg","title":"Belzutifan (Nierenzellkarzinom, fortgeschritten, nach ≥ 2 Vortherapien)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-04-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1195/","note":"Nierenzellkarzinom, fortgeschritten, nach ≥ 2 Vortherapien"},{"body":"G-BA","country":"Germany","drugId":"belzutifan","product":"Belzutifan","brand":"Welireg","title":"Belzutifan (Von Hippel-Lindau-Syndrom (VHL)-assoziierte Tumoren)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-04-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1196/","note":"Von Hippel-Lindau-Syndrom (VHL)-assoziierte Tumoren"},{"body":"G-BA","country":"Germany","drugId":"blinatumomab","product":"Blinatumomab","brand":"Blincyto","title":"Blinatumomab (Neues Anwendungsgebiet: Akute lymphatische B-Zell-Leukämie, Hochrisiko-Erstrezidiv, Ph-, CD19+, ≥1 Monat und <1 Jahr)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-03-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1185/","note":"Neues Anwendungsgebiet: Akute lymphatische B-Zell-Leukämie, Hochrisiko-Erstrezidiv, Ph-, CD19+, ≥1 Monat und <1 Jahr"},{"body":"G-BA","country":"Germany","drugId":"blinatumomab","product":"Blinatumomab","brand":"Blincyto","title":"Blinatumomab (Neues Anwendungsgebiet: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, neu diagnostiziert)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-03-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1186/","note":"Neues Anwendungsgebiet: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, neu diagnostiziert"},{"body":"G-BA","country":"Germany","drugId":"blinatumomab","product":"Blinatumomab","brand":"Blincyto","title":"Blinatumomab (Neues Anwendungsgebiet: Akute lymphatische B-​Zell-Leukämie, rezidiviert / refraktär, ≥ 1 Monat bis < 1 Jahr, nach ≥ 2 Vortherapien oder nach allogener Stammzelltransplantation)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-03-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1184/","note":"Neues Anwendungsgebiet: Akute lymphatische B-​Zell-Leukämie, rezidiviert / refraktär, ≥ 1 Monat bis < 1 Jahr, nach ≥ 2 Vortherapien oder nach allogener Stammzelltransplantation"},{"body":"G-BA","country":"Germany","drugId":"daratumumab","product":"Daratumumab","brand":"Darzalex","title":"Daratumumab (Neubewertung nach Fristablauf: systemische Leichtketten-Amyloidose, Erstlinie, Kombination mit Cyclophosphamid, Bortezomib und Dexamethason)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-03-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1187/","note":"Neubewertung nach Fristablauf: systemische Leichtketten-Amyloidose, Erstlinie, Kombination mit Cyclophosphamid, Bortezomib und Dexamethason"},{"body":"G-BA","country":"Germany","drugId":"fedratinib","product":"Fedratinib","brand":"Inrebic","title":"Fedratinib (Neubewertung nach Fristablauf: Myelofibrose)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-03-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1188/","note":"Neubewertung nach Fristablauf: Myelofibrose"},{"body":"G-BA","country":"Germany","drugId":"dostarlimab","product":"Dostarlimab","brand":"Jemperli","title":"Dostarlimab (Neues Anwendungsgebiet: primär fortgeschrittenes oder rezidiviertes Endometriumkarzinom mit pMMR, Kombination mit Carboplatin und Paclitaxel)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-02-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1175/","note":"Neues Anwendungsgebiet: primär fortgeschrittenes oder rezidiviertes Endometriumkarzinom mit pMMR, Kombination mit Carboplatin und Paclitaxel"},{"body":"G-BA","country":"Germany","drugId":"isatuximab","product":"Isatuximab","brand":"Sarclisa","title":"Isatuximab (Neues Anwendungsgebiet: Multiples Myelom, Erstlinie, Stammzelltransplantation ungeeignet, Kombination mit Bortezomib, Lenalidomid und Dexamethason)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-02-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1174/","note":"Neues Anwendungsgebiet: Multiples Myelom, Erstlinie, Stammzelltransplantation ungeeignet, Kombination mit Bortezomib, Lenalidomid und Dexamethason"},{"body":"G-BA","country":"Germany","drugId":"lazertinib","product":"Lazertinib","brand":"Lazcluze","title":"Lazertinib (Nicht-kleinzelliges Lungenkarzinom, EGFR-Exon19-Deletionen oder Exon 21-Substitutionsmutationen (L858R), Kombination mit Amivantamab)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-02-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1173/","note":"Nicht-kleinzelliges Lungenkarzinom, EGFR-Exon19-Deletionen oder Exon 21-Substitutionsmutationen (L858R), Kombination mit Amivantamab"},{"body":"G-BA","country":"Germany","drugId":"nintedanib","product":"Nintedanib","brand":"Ofev","title":"Nintedanib (Neues Anwendungsgebiet: interstitielle Lungenerkrankung mit systemischer Sklerose, 6 bis < 18 Jahre)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-02-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1176/","note":"Neues Anwendungsgebiet: interstitielle Lungenerkrankung mit systemischer Sklerose, 6 bis < 18 Jahre"},{"body":"G-BA","country":"Germany","drugId":"nintedanib","product":"Nintedanib","brand":"Ofev","title":"Nintedanib (Neues Anwendungsgebiet: klinisch signifikante progredient fibrosierende interstitielle Lungenerkrankungen, 6 bis < 18 Jahre)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-02-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1177/","note":"Neues Anwendungsgebiet: klinisch signifikante progredient fibrosierende interstitielle Lungenerkrankungen, 6 bis < 18 Jahre"},{"body":"G-BA","country":"Germany","drugId":"pirtobrutinib","product":"Pirtobrutinib","brand":"Jaypirca","title":"Pirtobrutinib (Mantelzell-Lymphom, vorbehandelte Patienten)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-02-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1126/","note":"Mantelzell-Lymphom, vorbehandelte Patienten"},{"body":"G-BA","country":"Germany","drugId":"amivantamab","product":"Amivantamab","brand":"Rybrevant","title":"Amivantamab (Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, EGFR Exon-19-Deletionen oder Exon-21-Substitutionsmutationen (L858R), Kombination mit Lazertinib)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-02-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1168/","note":"Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, EGFR Exon-19-Deletionen oder Exon-21-Substitutionsmutationen (L858R), Kombination mit Lazertinib"},{"body":"G-BA","country":"Germany","drugId":"amivantamab","product":"Amivantamab","brand":"Rybrevant","title":"Amivantamab (Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, EGFR Exon-19-Deletionen oder Exon-21-Substitutionsmutationen (L858R), vorbehandelt, Kombination mit Carboplatin und Pemetrexed)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-02-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1129/","note":"Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, EGFR Exon-19-Deletionen oder Exon-21-Substitutionsmutationen (L858R), vorbehandelt, Kombination mit Carboplatin und Pemetrexed"},{"body":"G-BA","country":"Germany","drugId":"amivantamab","product":"Amivantamab","brand":"Rybrevant","title":"Amivantamab (Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, EGFR Exon-20-Insertionsmutation, Erstlinie, Kombination mit Carboplatin und Pemetrexed)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-02-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1102/","note":"Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, EGFR Exon-20-Insertionsmutation, Erstlinie, Kombination mit Carboplatin und Pemetrexed"},{"body":"G-BA","country":"Germany","drugId":"osimertinib","product":"Osimertinib","brand":"Tagrisso","title":"Osimertinib (Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, EGFR-Mutationen, nach platinbasierter Radiochemotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-01-15","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1165/","note":"Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, EGFR-Mutationen, nach platinbasierter Radiochemotherapie"},{"body":"G-BA","country":"Germany","drugId":"erdafitinib","product":"Erdafitinib","brand":"Balversa","title":"Erdafitinib (Urothelkarzinom, FGFR3 Veränderungen, vorbehandelt mit PD-(L)1-Inhibitor)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-01-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1158/","note":"Urothelkarzinom, FGFR3 Veränderungen, vorbehandelt mit PD-(L)1-Inhibitor"},{"body":"G-BA","country":"Germany","drugId":"tislelizumab","product":"Tislelizumab","brand":"Tevimbra","title":"Tislelizumab (Neues Anwendungsgebiet: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, PD-L1-Expression ≥ 5, HER2-, Erstlinie, Kombination mit Platin- und Fluoropyrimidin-basierter Chemotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-01-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1163/","note":"Neues Anwendungsgebiet: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, PD-L1-Expression ≥ 5, HER2-, Erstlinie, Kombination mit Platin- und Fluoropyrimidin-basierter Chemotherapie"},{"body":"NICE","country":"UK","drugId":"enfortumab-vedotin","product":"Enfortumab vedotin","brand":"Padcev","title":"Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)","verdict":"mismatch","verdictLabel":"TA page does not name this product","date":"2024-06-13","url":"https://www.nice.org.uk/guidance/ta982","note":"Curated status recommended; the cited TA number may be wrong or renumbered"},{"body":"NICE","country":"UK","drugId":"epcoritamab","product":"Epcoritamab","brand":"Epkinly","title":"Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments","verdict":"cdf","verdictLabel":"Cancer Drugs Fund","date":"2024-03-06","url":"https://www.nice.org.uk/guidance/ta954","note":"Relapsed or refractory DLBCL after 2 or more systemic treatments"},{"body":"NICE","country":"UK","drugId":"relatlimab-nivolumab","product":"Relatlimab + nivolumab","brand":"Opdualag","title":"Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over","verdict":"recommended","verdictLabel":"Recommended","date":"2024-02-07","url":"https://www.nice.org.uk/guidance/ta950","note":"Untreated unresectable or metastatic melanoma (PD-L1 <1%)"},{"body":"NICE","country":"UK","drugId":"zanubrutinib","product":"Zanubrutinib","brand":"Brukinsa","title":"Zanubrutinib for treating chronic lymphocytic leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2023-11-22","url":"https://www.nice.org.uk/guidance/ta931","note":"Untreated CLL (with 17p/TP53 or unsuitable for FCR/BR) and CLL after 1 prior therapy"},{"body":"NICE","country":"UK","drugId":"glofitamab","product":"Glofitamab","brand":"Columvi","title":"Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments","verdict":"recommended","verdictLabel":"Recommended","date":"2023-10-17","url":"https://www.nice.org.uk/guidance/ta927","note":"Relapsed or refractory DLBCL after 2 or more systemic treatments"},{"body":"NICE","country":"UK","drugId":"tremelimumab","product":"Tremelimumab","brand":"Imjudo","title":"Bimekizumab for treating active psoriatic arthritis","verdict":"mismatch","verdictLabel":"TA page does not name this product","date":"2023-10-04","url":"https://www.nice.org.uk/guidance/ta916","note":"Curated status recommended; the cited TA number may be wrong or renumbered"},{"body":"NICE","country":"UK","drugId":"mosunetuzumab","product":"Mosunetuzumab","brand":"Lunsumio","title":"Mosunetuzumab for treating relapsed or refractory follicular lymphoma","verdict":"cdf","verdictLabel":"Cancer Drugs Fund","date":"2023-05-31","url":"https://www.nice.org.uk/guidance/ta892","note":"Relapsed or refractory follicular lymphoma after 2 or more systemic treatments"},{"body":"NICE","country":"UK","drugId":"sacituzumab-govitecan","product":"Sacituzumab govitecan","brand":"Trodelvy","title":"Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies","verdict":"recommended","verdictLabel":"Recommended","date":"2022-08-17","url":"https://www.nice.org.uk/guidance/ta819","note":"Unresectable triple-negative breast cancer after 2 or more systemic treatments"},{"body":"NICE","country":"UK","drugId":"alpelisib","product":"Alpelisib","brand":"Piqray","title":"Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2022-08-10","url":"https://www.nice.org.uk/guidance/ta816","note":"With fulvestrant for PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor"},{"body":"NICE","country":"UK","drugId":"asciminib","product":"Asciminib","brand":"Scemblix","title":"Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors","verdict":"recommended","verdictLabel":"Recommended","date":"2022-08-03","url":"https://www.nice.org.uk/guidance/ta813","note":"Chronic phase CML after 2 or more TKIs"},{"body":"NICE","country":"UK","drugId":"capmatinib-tepotinib","product":"Capmatinib & tepotinib","brand":"Tabrecta / Tepmetko","title":"Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations","verdict":"recommended","verdictLabel":"Recommended","date":"2022-05-18","url":"https://www.nice.org.uk/guidance/ta789","note":"Tepotinib for MET exon 14 skipping advanced NSCLC"},{"body":"NICE","country":"UK","drugId":"avelumab","product":"Avelumab","brand":"Bavencio","title":"Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy","verdict":"recommended","verdictLabel":"Recommended","date":"2022-05-11","url":"https://www.nice.org.uk/guidance/ta788","note":"Maintenance for urothelial cancer after platinum chemotherapy (JAVELIN Bladder 100)"},{"body":"NICE","country":"UK","drugId":"tucatinib","product":"Tucatinib","brand":"Tukysa","title":"Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies","verdict":"recommended","verdictLabel":"Recommended","date":"2022-04-27","url":"https://www.nice.org.uk/guidance/ta786","note":"With trastuzumab and capecitabine for HER2-positive breast cancer after 2 or more anti-HER2 treatments"},{"body":"NICE","country":"UK","drugId":"sotorasib","product":"Sotorasib","brand":"Lumakras","title":"Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer","verdict":"cdf","verdictLabel":"Cancer Drugs Fund","date":"2022-03-30","url":"https://www.nice.org.uk/guidance/ta781","note":"KRAS G12C-mutated advanced NSCLC after 1 or more systemic therapies"},{"body":"NICE","country":"UK","drugId":"dostarlimab","product":"Dostarlimab","brand":"Jemperli","title":"Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2022-03-16","url":"https://www.nice.org.uk/guidance/ta779","note":"dMMR/MSI-H recurrent or advanced endometrial cancer after platinum"},{"body":"NICE","country":"UK","drugId":"fedratinib","product":"Fedratinib","brand":"Inrebic","title":"Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2021-12-16","url":"https://www.nice.org.uk/guidance/ta756","note":"Myelofibrosis-related splenomegaly or symptoms after ruxolitinib"},{"body":"NICE","country":"UK","drugId":"selpercatinib","product":"Selpercatinib","brand":"Retevmo","title":"Selpercatinib for treating advanced thyroid cancer with RET alterations","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2021-11-03","url":"https://www.nice.org.uk/guidance/ta742","note":"RET fusion-positive advanced NSCLC after platinum chemotherapy"},{"body":"NICE","country":"UK","drugId":"apalutamide","product":"Apalutamide","brand":"Erleada","title":"Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2021-10-28","url":"https://www.nice.org.uk/guidance/ta740","note":"With ADT for hormone-sensitive metastatic prostate cancer"},{"body":"NICE","country":"UK","drugId":"pemigatinib","product":"Pemigatinib","brand":"Pemazyre","title":"Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement","verdict":"cdf","verdictLabel":"Cancer Drugs Fund","date":"2021-08-25","url":"https://www.nice.org.uk/guidance/ta722","note":"FGFR2 fusion or rearrangement-positive cholangiocarcinoma after 1 or more systemic therapies"},{"body":"NICE","country":"UK","drugId":"trastuzumab-deruxtecan","product":"Trastuzumab deruxtecan","brand":"Enhertu","title":"Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies","verdict":"cdf","verdictLabel":"Cancer Drugs Fund","date":"2021-05-26","url":"https://www.nice.org.uk/guidance/ta704","note":"HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 treatments"},{"body":"NICE","country":"UK","drugId":"acalabrutinib","product":"Acalabrutinib","brand":"Calquence","title":"Acalabrutinib for treating chronic lymphocytic leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2021-04-21","url":"https://www.nice.org.uk/guidance/ta689","note":"Untreated CLL (with 17p/TP53 or unsuitable for FCR/BR) and CLL after 1 prior therapy"},{"body":"NICE","country":"UK","drugId":"brexucabtagene-autoleucel","product":"Brexucabtagene autoleucel","brand":"Tecartus","title":"Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma","verdict":"cdf","verdictLabel":"Cancer Drugs Fund","date":"2021-02-24","url":"https://www.nice.org.uk/guidance/ta677","note":"Relapsed or refractory mantle cell lymphoma after a BTK inhibitor"},{"body":"NICE","country":"UK","drugId":"brigatinib","product":"Brigatinib","brand":"Alunbrig","title":"Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor","verdict":"recommended","verdictLabel":"Recommended","date":"2021-01-27","url":"https://www.nice.org.uk/guidance/ta670","note":"Untreated ALK-positive advanced NSCLC"},{"body":"NICE","country":"UK","drugId":"venetoclax","product":"Venetoclax","brand":"Venclexta","title":"Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2020-12-09","url":"https://www.nice.org.uk/guidance/ta663","note":"With obinutuzumab for untreated CLL"},{"body":"NICE","country":"UK","drugId":"darolutamide","product":"Darolutamide","brand":"Nubeqa","title":"Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2020-11-25","url":"https://www.nice.org.uk/guidance/ta660","note":"High-risk non-metastatic hormone-relapsed prostate cancer"},{"body":"NICE","country":"UK","drugId":"isatuximab","product":"Isatuximab","brand":"Sarclisa / Sarclisa Escena (SC)","title":"Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma","verdict":"cdf","verdictLabel":"Cancer Drugs Fund","date":"2020-11-18","url":"https://www.nice.org.uk/guidance/ta658","note":"With pomalidomide and dexamethasone for myeloma after 3 or more treatments"},{"body":"NICE","country":"UK","drugId":"osimertinib","product":"Osimertinib","brand":"Tagrisso","title":"Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer","verdict":"cdf","verdictLabel":"Cancer Drugs Fund","date":"2020-10-14","url":"https://www.nice.org.uk/guidance/ta654","note":"Untreated EGFR mutation-positive NSCLC (FLAURA)"},{"body":"NICE","country":"UK","drugId":"polatuzumab-vedotin","product":"Polatuzumab vedotin","brand":"Polivy","title":"Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma","verdict":"cdf","verdictLabel":"Cancer Drugs Fund","date":"2020-09-23","url":"https://www.nice.org.uk/guidance/ta649","note":"With bendamustine-rituximab for relapsed or refractory DLBCL not eligible for transplant"},{"body":"NICE","country":"UK","drugId":"glasdegib","product":"Glasdegib","brand":"Daurismo","title":"Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)","verdict":"mismatch","verdictLabel":"TA page does not name this product","date":"2020-09-02","url":"https://www.nice.org.uk/guidance/ta647","note":"Curated status recommended; the cited TA number may be wrong or renumbered"},{"body":"NICE","country":"UK","drugId":"entrectinib","product":"Entrectinib","brand":"Rozlytrek","title":"Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer","verdict":"cdf","verdictLabel":"Cancer Drugs Fund","date":"2020-08-12","url":"https://www.nice.org.uk/guidance/ta643","note":"NTRK fusion-positive solid tumours (histology-independent)"},{"body":"NICE","country":"UK","drugId":"gilteritinib","product":"Gilteritinib","brand":"Xospata","title":"Gilteritinib for treating relapsed or refractory acute myeloid leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2020-08-12","url":"https://www.nice.org.uk/guidance/ta642","note":"Relapsed or refractory FLT3 mutation-positive AML"},{"body":"NICE","country":"UK","drugId":"larotrectinib","product":"Larotrectinib","brand":"Vitrakvi","title":"Larotrectinib for treating NTRK fusion-positive solid tumours","verdict":"cdf","verdictLabel":"Cancer Drugs Fund","date":"2020-05-27","url":"https://www.nice.org.uk/guidance/ta630","note":"NTRK fusion-positive solid tumours (histology-independent)"},{"body":"NICE","country":"UK","drugId":"lorlatinib","product":"Lorlatinib","brand":"Lorbrena","title":"Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer","verdict":"cdf","verdictLabel":"Cancer Drugs Fund","date":"2020-05-13","url":"https://www.nice.org.uk/guidance/ta628","note":"ALK-positive NSCLC after alectinib, ceritinib or crizotinib then another TKI"},{"body":"NICE","country":"UK","drugId":"neratinib","product":"Neratinib","brand":"Nerlynx","title":"Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab","verdict":"recommended","verdictLabel":"Recommended","date":"2019-11-20","url":"https://www.nice.org.uk/guidance/ta612","note":"Extended adjuvant treatment of HR-positive, HER2-positive early breast cancer completed less than 1 year after trastuzumab"},{"body":"NICE","country":"UK","drugId":"rucaparib","product":"Rucaparib","brand":"Rubraca","title":"Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2019-11-13","url":"https://www.nice.org.uk/guidance/ta611","note":"Maintenance for relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer"},{"body":"NICE","country":"UK","drugId":"dacomitinib","product":"Dacomitinib","brand":"Vizimpro","title":"Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2019-08-14","url":"https://www.nice.org.uk/guidance/ta595","note":"Untreated EGFR mutation-positive NSCLC"},{"body":"NICE","country":"UK","drugId":"cemiplimab","product":"Cemiplimab","brand":"Libtayo","title":"Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2019-08-07","url":"https://www.nice.org.uk/guidance/ta592","note":"Advanced cutaneous squamous cell carcinoma"},{"body":"NICE","country":"UK","drugId":"durvalumab","product":"Durvalumab","brand":"Imfinzi","title":"Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2019-05-01","url":"https://www.nice.org.uk/guidance/ta578","note":"Unresectable stage III NSCLC after chemoradiation (PACIFIC)"},{"body":"NICE","country":"UK","drugId":"daratumumab","product":"Daratumumab","brand":"Darzalex / Darzalex Faspro (SC)","title":"Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2019-04-10","url":"https://www.nice.org.uk/guidance/ta573","note":"With bortezomib and dexamethasone for myeloma after 1 prior therapy (CASTOR)"},{"body":"NICE","country":"UK","drugId":"abemaciclib","product":"Abemaciclib","brand":"Verzenio","title":"Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2019-02-27","url":"https://www.nice.org.uk/guidance/ta563","note":"With an aromatase inhibitor for untreated HR-positive, HER2-negative advanced breast cancer"},{"body":"NICE","country":"UK","drugId":"encorafenib","product":"Encorafenib","brand":"Braftovi","title":"Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma","verdict":"recommended","verdictLabel":"Recommended","date":"2019-02-27","url":"https://www.nice.org.uk/guidance/ta562","note":"With binimetinib for BRAF V600 mutation-positive melanoma"},{"body":"NICE","country":"UK","drugId":"binimetinib","product":"Binimetinib","brand":"Mektovi","title":"Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma","verdict":"recommended","verdictLabel":"Recommended","date":"2019-02-27","url":"https://www.nice.org.uk/guidance/ta562","note":"With encorafenib for BRAF V600 mutation-positive melanoma"},{"body":"NICE","country":"UK","drugId":"axicabtagene-ciloleucel","product":"Axicabtagene ciloleucel","brand":"Yescarta","title":"Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2019-01-23","url":"https://www.nice.org.uk/guidance/ta559","note":"Relapsed or refractory DLBCL or PMBCL after 2 or more systemic therapies"},{"body":"NICE","country":"UK","drugId":"regorafenib","product":"Regorafenib","brand":"Stivarga","title":"Regorafenib for previously treated advanced hepatocellular carcinoma","verdict":"recommended","verdictLabel":"Recommended","date":"2019-01-09","url":"https://www.nice.org.uk/guidance/ta555","note":"Advanced HCC after sorafenib"},{"body":"NICE","country":"UK","drugId":"tisagenlecleucel","product":"Tisagenlecleucel","brand":"Kymriah","title":"Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2018-12-21","url":"https://www.nice.org.uk/guidance/ta554","note":"Relapsed or refractory B-cell ALL in people up to 25 years"},{"body":"NICE","country":"UK","drugId":"lenvatinib","product":"Lenvatinib","brand":"Lenvima","title":"Lenvatinib for untreated advanced hepatocellular carcinoma","verdict":"recommended","verdictLabel":"Recommended","date":"2018-12-19","url":"https://www.nice.org.uk/guidance/ta551","note":"Untreated advanced HCC"},{"body":"NICE","country":"UK","drugId":"cpx-351","product":"CPX-351 (liposomal daunorubicin-cytarabine)","brand":"Vyxeos","title":"Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2018-12-19","url":"https://www.nice.org.uk/guidance/ta552","note":"Untreated therapy-related AML or AML with myelodysplasia-related changes"},{"body":"NICE","country":"UK","drugId":"gemtuzumab-ozogamicin","product":"Gemtuzumab ozogamicin","brand":"Mylotarg","title":"Gemtuzumab ozogamicin for untreated acute myeloid leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2018-11-14","url":"https://www.nice.org.uk/guidance/ta545","note":"Untreated de novo CD33-positive AML with standard induction chemotherapy"},{"body":"NICE","country":"UK","drugId":"inotuzumab-ozogamicin","product":"Inotuzumab ozogamicin","brand":"Besponsa","title":"Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2018-09-19","url":"https://www.nice.org.uk/guidance/ta541","note":"Relapsed or refractory CD22-positive B-cell precursor ALL"},{"body":"NICE","country":"UK","drugId":"lutathera","product":"Lutetium-177 dotatate","brand":"Lutathera","title":"Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours","verdict":"recommended","verdictLabel":"Recommended","date":"2018-08-29","url":"https://www.nice.org.uk/guidance/ta539","note":"Unresectable or metastatic, progressive, well-differentiated somatostatin receptor-positive GEP-NETs"},{"body":"NICE","country":"UK","drugId":"dinutuximab","product":"Dinutuximab (ch14.18) / dinutuximab beta","brand":"Unituxin / Qarziba (EU)","title":"Dinutuximab beta for treating neuroblastoma","verdict":"recommended","verdictLabel":"Recommended","date":"2018-08-22","url":"https://www.nice.org.uk/guidance/ta538","note":"High-risk neuroblastoma after induction, high-dose chemotherapy and stem cell transplant, or relapsed/refractory"},{"body":"NICE","country":"UK","drugId":"alectinib","product":"Alectinib","brand":"Alecensa","title":"Alectinib for untreated ALK-positive advanced non-small-cell lung cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2018-08-08","url":"https://www.nice.org.uk/guidance/ta536","note":"Untreated ALK-positive advanced NSCLC"},{"body":"NICE","country":"UK","drugId":"pembrolizumab","product":"Pembrolizumab","brand":"Keytruda / Keytruda Qlex (SC)","title":"Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer","verdict":"optimised","verdictLabel":"Recommended (optimised)","date":"2018-07-18","url":"https://www.nice.org.uk/guidance/ta531","note":"Untreated PD-L1 ≥50% metastatic NSCLC (2-year stopping rule)"},{"body":"NICE","country":"UK","drugId":"niraparib","product":"Niraparib","brand":"Zejula","title":"Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2018-07-04","url":"https://www.nice.org.uk/guidance/ta528","note":"Maintenance for relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer"},{"body":"NICE","country":"UK","drugId":"midostaurin","product":"Midostaurin","brand":"Rydapt","title":"Midostaurin for untreated acute myeloid leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2018-06-13","url":"https://www.nice.org.uk/guidance/ta523","note":"Untreated FLT3 mutation-positive AML with standard chemotherapy"},{"body":"NICE","country":"UK","drugId":"arsenic-trioxide","product":"Arsenic trioxide","brand":"Trisenox","title":"Arsenic trioxide for treating acute promyelocytic leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2018-06-13","url":"https://www.nice.org.uk/guidance/ta526","note":"Acute promyelocytic leukaemia (untreated low-to-intermediate risk with ATRA, and relapsed)"},{"body":"NICE","country":"UK","drugId":"atezolizumab","product":"Atezolizumab","brand":"Tecentriq / Tecentriq Hybreza (SC)","title":"Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy","verdict":"recommended","verdictLabel":"Recommended","date":"2018-05-16","url":"https://www.nice.org.uk/guidance/ta520","note":"NSCLC after chemotherapy"},{"body":"NICE","country":"UK","drugId":"tivozanib","product":"Tivozanib","brand":"Fotivda","title":"Tivozanib for treating advanced renal cell carcinoma","verdict":"recommended","verdictLabel":"Recommended","date":"2018-03-21","url":"https://www.nice.org.uk/guidance/ta512","note":"First-line advanced RCC"},{"body":"NICE","country":"UK","drugId":"pertuzumab","product":"Pertuzumab","brand":"Perjeta; Phesgo (with trastuzumab, subcutaneous)","title":"Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2018-03-07","url":"https://www.nice.org.uk/guidance/ta509","note":"With trastuzumab and docetaxel for HER2-positive metastatic breast cancer"},{"body":"NICE","country":"UK","drugId":"ixazomib","product":"Ixazomib","brand":"Ninlaro","title":"Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2018-02-07","url":"https://www.nice.org.uk/guidance/ta505","note":"With lenalidomide and dexamethasone for myeloma after 2 or 3 lines"},{"body":"NICE","country":"UK","drugId":"ceritinib","product":"Ceritinib","brand":"Zykadia","title":"Ceritinib for untreated ALK-positive non-small-cell lung cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2018-01-24","url":"https://www.nice.org.uk/guidance/ta500","note":"Untreated ALK-positive advanced NSCLC"},{"body":"NICE","country":"UK","drugId":"palbociclib","product":"Palbociclib","brand":"Ibrance","title":"Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2017-12-20","url":"https://www.nice.org.uk/guidance/ta495","note":"With an aromatase inhibitor for untreated HR-positive, HER2-negative advanced breast cancer"},{"body":"NICE","country":"UK","drugId":"ribociclib","product":"Ribociclib","brand":"Kisqali","title":"Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2017-12-20","url":"https://www.nice.org.uk/guidance/ta496","note":"With an aromatase inhibitor for untreated HR-positive, HER2-negative advanced breast cancer"},{"body":"NICE","country":"UK","drugId":"vismodegib","product":"Vismodegib","brand":"Erivedge","title":"Vismodegib for treating basal cell carcinoma","verdict":"not recommended","verdictLabel":"Not recommended","date":"2017-11-22","url":"https://www.nice.org.uk/guidance/ta489","note":"Symptomatic metastatic or locally advanced basal cell carcinoma unsuitable for surgery or radiotherapy"},{"body":"NICE","country":"UK","drugId":"nivolumab","product":"Nivolumab","brand":"Opdivo / Opdivo Qvantig (SC)","title":"Nivolumab for previously treated non-squamous non-small-cell lung cancer","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2017-11-01","url":"https://www.nice.org.uk/guidance/ta484","note":"Previously treated non-squamous NSCLC"},{"body":"NICE","country":"UK","drugId":"paclitaxel","product":"Paclitaxel / nab-paclitaxel","brand":"Taxol / Abraxane","title":"Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2017-09-06","url":"https://www.nice.org.uk/guidance/ta476","note":"Nab-paclitaxel with gemcitabine for untreated metastatic pancreatic cancer"},{"body":"NICE","country":"UK","drugId":"sorafenib","product":"Sorafenib","brand":"Nexavar","title":"Sorafenib for treating advanced hepatocellular carcinoma","verdict":"recommended","verdictLabel":"Recommended","date":"2017-09-06","url":"https://www.nice.org.uk/guidance/ta474","note":"Advanced HCC (Child-Pugh A)"},{"body":"NICE","country":"UK","drugId":"cabozantinib","product":"Cabozantinib","brand":"Cabometyx","title":"Cabozantinib for previously treated advanced renal cell carcinoma","verdict":"recommended","verdictLabel":"Recommended","date":"2017-08-09","url":"https://www.nice.org.uk/guidance/ta463","note":"Advanced RCC after VEGF-targeted therapy"},{"body":"NICE","country":"UK","drugId":"trastuzumab-emtansine","product":"Trastuzumab emtansine","brand":"Kadcyla","title":"Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane","verdict":"recommended","verdictLabel":"Recommended","date":"2017-07-19","updated":"2017-11-20","url":"https://www.nice.org.uk/guidance/ta458","note":"HER2-positive metastatic breast cancer after trastuzumab and a taxane"},{"body":"NICE","country":"UK","drugId":"carfilzomib","product":"Carfilzomib","brand":"Kyprolis","title":"Carfilzomib for previously treated multiple myeloma","verdict":"recommended","verdictLabel":"Recommended","date":"2017-07-19","url":"https://www.nice.org.uk/guidance/ta457","note":"With dexamethasone for myeloma after 1 prior therapy"},{"body":"NICE","country":"UK","drugId":"brentuximab-vedotin","product":"Brentuximab vedotin","brand":"Adcetris","title":"Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2017-06-28","url":"https://www.nice.org.uk/guidance/ta446","note":"CD30-positive Hodgkin lymphoma after autologous transplant or 2 prior therapies"},{"body":"NICE","country":"UK","drugId":"blinatumomab","product":"Blinatumomab","brand":"Blincyto","title":"Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2017-06-28","url":"https://www.nice.org.uk/guidance/ta450","note":"Philadelphia-negative relapsed or refractory B-cell precursor ALL"},{"body":"NICE","country":"UK","drugId":"ponatinib","product":"Ponatinib","brand":"Iclusig","title":"Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2017-06-28","url":"https://www.nice.org.uk/guidance/ta451","note":"CML or Ph-positive ALL resistant to dasatinib or nilotinib, or with T315I"},{"body":"NICE","country":"UK","drugId":"cetuximab","product":"Cetuximab","brand":"Erbitux","title":"Cetuximab and panitumumab for previously untreated metastatic colorectal cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2017-03-29","updated":"2017-09-25","url":"https://www.nice.org.uk/guidance/ta439","note":"With chemotherapy for untreated RAS wild-type metastatic colorectal cancer"},{"body":"NICE","country":"UK","drugId":"panitumumab","product":"Panitumumab","brand":"Vectibix","title":"Cetuximab and panitumumab for previously untreated metastatic colorectal cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2017-03-29","updated":"2017-09-25","url":"https://www.nice.org.uk/guidance/ta439","note":"With chemotherapy for untreated RAS wild-type metastatic colorectal cancer"},{"body":"NICE","country":"UK","drugId":"everolimus","product":"Everolimus","brand":"Afinitor","title":"Everolimus for advanced renal cell carcinoma after previous treatment","verdict":"recommended","verdictLabel":"Recommended","date":"2017-02-22","url":"https://www.nice.org.uk/guidance/ta432","note":"Advanced renal cell carcinoma after previous treatment"},{"body":"NICE","country":"UK","drugId":"ibrutinib","product":"Ibrutinib","brand":"Imbruvica","title":"Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation","verdict":"recommended","verdictLabel":"Recommended","date":"2017-01-25","url":"https://www.nice.org.uk/guidance/ta429","note":"CLL after 1 prior therapy, or untreated CLL with 17p deletion or TP53 mutation"},{"body":"NICE","country":"UK","drugId":"pomalidomide","product":"Pomalidomide","brand":"Pomalyst / Imnovid","title":"Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib","verdict":"recommended","verdictLabel":"Recommended","date":"2017-01-11","url":"https://www.nice.org.uk/guidance/ta427","note":"Multiple myeloma after 3 or more treatments including lenalidomide and bortezomib"},{"body":"NICE","country":"UK","drugId":"eribulin","product":"Eribulin","brand":"Halaven","title":"Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens","verdict":"recommended","verdictLabel":"Recommended","date":"2016-12-21","url":"https://www.nice.org.uk/guidance/ta423","note":"Locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens"},{"body":"NICE","country":"UK","drugId":"dasatinib","product":"Dasatinib","brand":"Sprycel","title":"Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2016-12-21","url":"https://www.nice.org.uk/guidance/ta426","note":"CML resistant or intolerant to imatinib"},{"body":"NICE","country":"UK","drugId":"cobimetinib","product":"Cobimetinib","brand":"Cotellic","title":"Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma","verdict":"recommended","verdictLabel":"Recommended","date":"2016-10-26","url":"https://www.nice.org.uk/guidance/ta414","note":"With vemurafenib for BRAF V600 mutation-positive melanoma"},{"body":"NICE","country":"UK","drugId":"talimogene-laherparepvec","product":"Talimogene laherparepvec","brand":"Imlygic","title":"Talimogene laherparepvec for treating unresectable metastatic melanoma","verdict":"recommended","verdictLabel":"Recommended","date":"2016-09-28","url":"https://www.nice.org.uk/guidance/ta410","note":"Unresectable regionally or distantly metastatic melanoma (stage IIIB-IVM1a) when systemically administered immunotherapy is not suitable"},{"body":"NICE","country":"UK","drugId":"crizotinib","product":"Crizotinib","brand":"Xalkori","title":"Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2016-09-28","url":"https://www.nice.org.uk/guidance/ta406","note":"Untreated ALK-positive advanced NSCLC"},{"body":"NICE","country":"UK","drugId":"radium-223","product":"Radium-223 dichloride","brand":"Xofigo","title":"Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases","verdict":"recommended","verdictLabel":"Recommended","date":"2016-09-28","url":"https://www.nice.org.uk/guidance/ta412","note":"Hormone-relapsed prostate cancer with bone metastases after docetaxel (or not suitable for it)"},{"body":"NICE","country":"UK","drugId":"asparaginase","product":"Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)","brand":"Oncaspar / Asparlas / Rylaze / Erwinaze","title":"Pegaspargase for treating acute lymphoblastic leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2016-09-28","url":"https://www.nice.org.uk/guidance/ta408","note":"Acute lymphoblastic leukaemia in children, young people and adults"},{"body":"NICE","country":"UK","drugId":"trifluridine-tipiracil","product":"Trifluridine/tipiracil","brand":"Lonsurf","title":"Trifluridine–tipiracil for previously treated metastatic colorectal cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2016-08-24","url":"https://www.nice.org.uk/guidance/ta405","note":"Metastatic colorectal cancer after standard therapies"},{"body":"NICE","country":"UK","drugId":"degarelix","product":"Degarelix","brand":"Firmagon","title":"Degarelix for treating advanced hormone-dependent prostate cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2016-08-24","url":"https://www.nice.org.uk/guidance/ta404","note":"Advanced hormone-dependent prostate cancer with spinal metastases"},{"body":"NICE","country":"UK","drugId":"bosutinib","product":"Bosutinib","brand":"Bosulif","title":"Bosutinib for previously treated chronic myeloid leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2016-08-24","url":"https://www.nice.org.uk/guidance/ta401","note":"CML after prior TKI when imatinib, nilotinib and dasatinib are not appropriate"},{"body":"NICE","country":"UK","drugId":"dabrafenib-trametinib","product":"Dabrafenib + trametinib","brand":"Tafinlar + Mekinist","title":"Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma","verdict":"recommended","verdictLabel":"Recommended","date":"2016-06-22","url":"https://www.nice.org.uk/guidance/ta396","note":"Unresectable or metastatic BRAF V600-mutated melanoma"},{"body":"NICE","country":"UK","drugId":"cabazitaxel","product":"Cabazitaxel","brand":"Jevtana","title":"Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel","verdict":"recommended","verdictLabel":"Recommended","date":"2016-05-25","updated":"2016-08-24","url":"https://www.nice.org.uk/guidance/ta391","note":"Metastatic hormone-relapsed prostate cancer after docetaxel"},{"body":"NICE","country":"UK","drugId":"ruxolitinib","product":"Ruxolitinib","brand":"Jakafi / Jakavi","title":"Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis","verdict":"recommended","verdictLabel":"Recommended","date":"2016-03-23","url":"https://www.nice.org.uk/guidance/ta386","note":"Disease-related splenomegaly or symptoms in myelofibrosis (intermediate-2 or high risk)"},{"body":"NICE","country":"UK","drugId":"olaparib","product":"Olaparib","brand":"Lynparza","title":"Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2016-01-27","url":"https://www.nice.org.uk/guidance/ta381","note":"Maintenance for relapsed platinum-sensitive BRCA-mutated ovarian cancer"},{"body":"NICE","country":"UK","drugId":"ramucirumab","product":"Ramucirumab","brand":"Cyramza","title":"Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy","verdict":"not recommended","verdictLabel":"Not recommended","date":"2016-01-27","url":"https://www.nice.org.uk/guidance/ta378","note":"Advanced gastric or gastro-oesophageal junction cancer after chemotherapy"},{"body":"NICE","country":"UK","drugId":"idelalisib","product":"Idelalisib","brand":"Zydelig","title":"Idelalisib for treating chronic lymphocytic leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2015-10-28","url":"https://www.nice.org.uk/guidance/ta359","note":"With rituximab for CLL after 1 prior therapy or untreated with 17p/TP53"},{"body":"NICE","country":"UK","drugId":"obinutuzumab","product":"Obinutuzumab","brand":"Gazyva","title":"Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2015-06-02","url":"https://www.nice.org.uk/guidance/ta343","note":"With chlorambucil for untreated CLL unsuitable for fludarabine-based therapy"},{"body":"NICE","country":"UK","drugId":"axitinib","product":"Axitinib","brand":"Inlyta","title":"Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment","verdict":"recommended","verdictLabel":"Recommended","date":"2015-02-25","url":"https://www.nice.org.uk/guidance/ta333","note":"Advanced RCC after failure of prior systemic treatment"},{"body":"NICE","country":"UK","drugId":"sipuleucel-t","product":"Sipuleucel-T","brand":"Provenge","title":"Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer","verdict":"not recommended","verdictLabel":"Not recommended","date":"2015-02-23","url":"https://www.nice.org.uk/guidance/ta332","note":"Asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer"},{"body":"NICE","country":"UK","drugId":"ipilimumab","product":"Ipilimumab","brand":"Yervoy","title":"Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma","verdict":"recommended","verdictLabel":"Recommended","date":"2014-07-23","url":"https://www.nice.org.uk/guidance/ta319","note":"Previously untreated advanced melanoma"},{"body":"NICE","country":"UK","drugId":"enzalutamide","product":"Enzalutamide","brand":"Xtandi","title":"Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen","verdict":"recommended","verdictLabel":"Recommended","date":"2014-07-23","url":"https://www.nice.org.uk/guidance/ta316","note":"Metastatic castration-resistant prostate cancer after docetaxel"},{"body":"NICE","country":"UK","drugId":"afatinib","product":"Afatinib","brand":"Gilotrif / Giotrif","title":"Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2014-04-23","url":"https://www.nice.org.uk/guidance/ta310","note":"Untreated EGFR mutation-positive NSCLC"},{"body":"NICE","country":"UK","drugId":"vemurafenib","product":"Vemurafenib","brand":"Zelboraf","title":"Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma","verdict":"recommended","verdictLabel":"Recommended","date":"2012-12-12","updated":"2015-01-01","url":"https://www.nice.org.uk/guidance/ta269","note":"BRAF V600 mutation-positive unresectable or metastatic melanoma"},{"body":"NICE","country":"UK","drugId":"lapatinib","product":"Lapatinib","brand":"Tykerb","title":"Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2","verdict":"not recommended","verdictLabel":"Not recommended","date":"2012-06-27","url":"https://www.nice.org.uk/guidance/ta257","note":"With an aromatase inhibitor for HER2-positive, HR-positive metastatic breast cancer"},{"body":"NICE","country":"UK","drugId":"erlotinib","product":"Erlotinib","brand":"Tarceva","title":"Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2012-06-27","url":"https://www.nice.org.uk/guidance/ta258","note":"Untreated EGFR mutation-positive NSCLC"},{"body":"NICE","country":"UK","drugId":"abiraterone","product":"Abiraterone acetate","brand":"Zytiga (generic)","title":"Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen","verdict":"recommended","verdictLabel":"Recommended","date":"2012-06-27","updated":"2016-07-27","url":"https://www.nice.org.uk/guidance/ta259","note":"Metastatic castration-resistant prostate cancer after docetaxel"},{"body":"NICE","country":"UK","drugId":"nilotinib","product":"Nilotinib","brand":"Tasigna","title":"Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2012-04-25","url":"https://www.nice.org.uk/guidance/ta251","note":"Untreated chronic phase CML (dasatinib, nilotinib and standard-dose imatinib)"},{"body":"NICE","country":"UK","drugId":"fulvestrant","product":"Fulvestrant","brand":"Faslodex","title":"Fulvestrant for the treatment of locally advanced or metastatic breast cancer","verdict":"not recommended","verdictLabel":"Not recommended","date":"2011-12-14","url":"https://www.nice.org.uk/guidance/ta239","note":"Locally advanced or metastatic breast cancer as monotherapy"},{"body":"NICE","country":"UK","drugId":"mifamurtide","product":"Mifamurtide","brand":"Mepact","title":"Mifamurtide for the treatment of osteosarcoma","verdict":"recommended","verdictLabel":"Recommended","date":"2011-10-26","url":"https://www.nice.org.uk/guidance/ta235","note":"High-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection (age 2-30)"},{"body":"NICE","country":"UK","drugId":"thalidomide","product":"Thalidomide","brand":"Thalomid","title":"Bortezomib and thalidomide for the first‑line treatment of multiple myeloma","verdict":"recommended","verdictLabel":"Recommended","date":"2011-07-27","url":"https://www.nice.org.uk/guidance/ta228","note":"Untreated multiple myeloma with an alkylating agent and a corticosteroid (transplant-ineligible)"},{"body":"NICE","country":"UK","drugId":"azacitidine","product":"Azacitidine","brand":"Vidaza / Onureg (oral)","title":"Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2011-03-23","url":"https://www.nice.org.uk/guidance/ta218","note":"Intermediate-2 or high-risk MDS, CMML, and AML with 20-30% blasts not eligible for transplant"},{"body":"NICE","country":"UK","drugId":"pazopanib","product":"Pazopanib","brand":"Votrient","title":"Pazopanib for the first-line treatment of advanced renal cell carcinoma","verdict":"recommended","verdictLabel":"Recommended","date":"2011-02-23","updated":"2013-08-01","url":"https://www.nice.org.uk/guidance/ta215","note":"First-line advanced RCC"},{"body":"NICE","country":"UK","drugId":"bendamustine","product":"Bendamustine","brand":"Treanda / Bendeka / Belrapzo","title":"Bendamustine for the first-line treatment of chronic lymphocytic leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2011-02-23","url":"https://www.nice.org.uk/guidance/ta216","note":"First-line CLL (Binet B/C) when fludarabine combination is not appropriate"},{"body":"NICE","country":"UK","drugId":"bevacizumab","product":"Bevacizumab","brand":"Avastin (and biosimilars)","title":"Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2010-12-15","url":"https://www.nice.org.uk/guidance/ta212","note":"Metastatic colorectal cancer with oxaliplatin or fluorouracil-based chemotherapy"},{"body":"NICE","country":"UK","drugId":"gefitinib","product":"Gefitinib","brand":"Iressa","title":"Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2010-07-28","url":"https://www.nice.org.uk/guidance/ta192","note":"Untreated EGFR mutation-positive NSCLC"},{"body":"NICE","country":"UK","drugId":"trabectedin","product":"Trabectedin","brand":"Yondelis","title":"Trabectedin for the treatment of advanced soft tissue sarcoma","verdict":"recommended","verdictLabel":"Recommended","date":"2010-02-24","updated":"2021-02-08","url":"https://www.nice.org.uk/guidance/ta185","note":"Advanced soft tissue sarcoma after anthracyclines and ifosfamide"},{"body":"NICE","country":"UK","drugId":"topotecan","product":"Topotecan","brand":"Hycamtin","title":"Topotecan for the treatment of relapsed small-cell lung cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2009-11-25","url":"https://www.nice.org.uk/guidance/ta184","note":"Relapsed small-cell lung cancer"},{"body":"NICE","country":"UK","drugId":"pemetrexed","product":"Pemetrexed","brand":"Alimta (and generics)","title":"Pemetrexed for the first-line treatment of non-small-cell lung cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2009-09-23","url":"https://www.nice.org.uk/guidance/ta181","note":"First-line treatment of non-squamous NSCLC with cisplatin"},{"body":"NICE","country":"UK","drugId":"temsirolimus","product":"Temsirolimus","brand":"Torisel","title":"Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma","verdict":"not recommended","verdictLabel":"Not recommended","date":"2009-08-26","url":"https://www.nice.org.uk/guidance/ta178","note":"First-line poor-prognosis advanced RCC"},{"body":"NICE","country":"UK","drugId":"lenalidomide","product":"Lenalidomide","brand":"Revlimid","title":"Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies","verdict":"recommended","verdictLabel":"Recommended","date":"2009-06-18","updated":"2019-06-26","url":"https://www.nice.org.uk/guidance/ta171","note":"Multiple myeloma after 2 or more prior therapies"},{"body":"NICE","country":"UK","drugId":"sunitinib","product":"Sunitinib","brand":"Sutent","title":"Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma","verdict":"recommended","verdictLabel":"Recommended","date":"2009-03-25","url":"https://www.nice.org.uk/guidance/ta169","note":"First-line advanced or metastatic RCC"},{"body":"NICE","country":"UK","drugId":"bortezomib","product":"Bortezomib","brand":"Velcade","title":"Bortezomib monotherapy for relapsed multiple myeloma","verdict":"recommended","verdictLabel":"Recommended","date":"2007-10-23","url":"https://www.nice.org.uk/guidance/ta129","note":"Multiple myeloma at first relapse"},{"body":"NICE","country":"UK","drugId":"letrozole","product":"Letrozole (and other aromatase inhibitors)","brand":"Femara; anastrozole (Arimidex); exemestane (Aromasin)","title":"Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer","verdict":"mismatch","verdictLabel":"TA page does not name this product","date":"2006-11-22","url":"https://www.nice.org.uk/guidance/ta112","note":"Curated status recommended; the cited TA number may be wrong or renumbered"},{"body":"NICE","country":"UK","drugId":"irinotecan","product":"Irinotecan (and liposomal irinotecan)","brand":"Camptosar / Onivyde","title":"Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2005-08-24","url":"https://www.nice.org.uk/guidance/ta93","note":"Irinotecan, oxaliplatin and raltitrexed for advanced colorectal cancer"},{"body":"NICE","country":"UK","drugId":"oxaliplatin","product":"Oxaliplatin","brand":"Eloxatin","title":"Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2005-08-24","url":"https://www.nice.org.uk/guidance/ta93","note":"Advanced colorectal cancer (FOLFOX-type regimens)"},{"body":"NICE","country":"UK","drugId":"pegylated-liposomal-doxorubicin","product":"Pegylated liposomal doxorubicin","brand":"Doxil / Caelyx","title":"Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2005-05-25","url":"https://www.nice.org.uk/guidance/ta91","note":"Advanced ovarian cancer after first-line platinum chemotherapy"},{"body":"NICE","country":"UK","drugId":"imatinib","product":"Imatinib","brand":"Gleevec","title":"Guidance on the use of imatinib for chronic myeloid leukaemia","verdict":"recommended","verdictLabel":"Recommended","date":"2003-10-22","updated":"2016-01-21","url":"https://www.nice.org.uk/guidance/ta70","note":"Chronic phase CML (first-line)"},{"body":"NICE","country":"UK","drugId":"rituximab","product":"Rituximab","brand":"Rituxan / MabThera (and biosimilars)","title":"Rituximab for aggressive non-Hodgkin's lymphoma","verdict":"recommended","verdictLabel":"Recommended","date":"2003-09-24","url":"https://www.nice.org.uk/guidance/ta65","note":"Aggressive (diffuse large B-cell) non-Hodgkin lymphoma with CHOP"},{"body":"NICE","country":"UK","drugId":"trastuzumab","product":"Trastuzumab","brand":"Herceptin (and biosimilars, Phesgo with pertuzumab)","title":"Guidance on the use of trastuzumab for the treatment of advanced breast cancer","verdict":"recommended","verdictLabel":"Recommended","date":"2002-03-15","url":"https://www.nice.org.uk/guidance/ta34","note":"HER2-positive advanced breast cancer"},{"body":"NICE","country":"UK","drugId":"gemcitabine","product":"Gemcitabine","brand":"Gemzar / Infugem","title":"Guidance on the use of gemcitabine for the treatment of pancreatic cancer","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2001-05-08","url":"https://www.nice.org.uk/guidance/ta25","note":"Advanced pancreatic cancer"}],"errors":[],"bodies":{"NICE":{"name":"National Institute for Health and Care Excellence","country":"United Kingdom (England and Wales)","url":"https://www.nice.org.uk/guidance/published?ngt=Technology%20appraisal%20guidance","method":"Each TA cited in coverage-uk.ts is fetched to confirm title, publication date and withdrawal status","checked":128,"ok":128,"failed":0},"G-BA":{"name":"Gemeinsamer Bundesausschuss","country":"Germany","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/","method":"First 8 pages of the early benefit assessment register, matched to corpus products by active substance","checked":8,"ok":8,"failed":0},"PBAC":{"name":"Pharmaceutical Benefits Advisory Committee","country":"Australia","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes","method":"Latest meetings listed with links to the outcome documents (PDF; verdicts not extracted)","checked":1,"ok":1,"failed":0,"note":"6 most recent meetings listed"}}}